Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.

Dennis, M; Culligan, D; Karamitros, D; Vyas, P; Johnson, P; Russell, N H; Cavenagh, J; Szubert, A; Hartley, S; Brown, J; Bowen, D

Dennis, M; Culligan, D; Karamitros, D; Vyas, P; Johnson, P; Russell, N H; Cavenagh, J; Szubert, A; Hartley, S; Brown, J; Bowen, D.

Afiliação

Dennis M; Christie Hospital, Manchester, United Kingdom.
Culligan D; Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
Karamitros D; John Radcliffe Hospital, Oxford, United Kingdom.
Vyas P; John Radcliffe Hospital, Oxford, United Kingdom.
Johnson P; Western General Hospital, Edinburgh, United Kingdom.
Russell NH; Nottingham University Hospital, Nottingham, United Kingdom.
Cavenagh J; St. Bartholomew's Hospital, London, United Kingdom.
Szubert A; Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom.
Hartley S; Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom.
Brown J; Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom.
Bowen D; St. James's Institute of Oncology, Leeds, United Kingdom.

Leuk Res Rep ; 2(2): 70-4, 2013.

Article em En | MEDLINE | ID: mdl-24371786

Palavras-chave

Acute myeloid leukaemia; Chemotherapy; Chromosome 5; Lenalidomide; Myelodysplasia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Leuk Res Rep Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google